SCHEDULE 13D/A: Moshe Arkin and M. Arkin Dermatology Significantly Increase Stake in Sol-Gel Technologies to Over 65%

Moshe Arkin and M. Arkin Dermatology Ltd. have significantly increased their beneficial ownership in Sol-Gel Technologies Ltd., now holding an aggregate of 65.31% of the outstanding Ordinary Shares through recent open market purchases.

Summary

• Moshe Arkin, individually and through M. Arkin Dermatology Ltd., has increased his beneficial ownership in Sol-Gel Technologies Ltd. (SGLT).
• As of June 11, 2025, M. Arkin Dermatology Ltd. directly owns 1,806,856 Ordinary Shares, representing approximately 60.52% of the Company's outstanding shares.
• Moshe Arkin directly owns 143,257 Ordinary Shares, representing approximately 5.14% of the Company's outstanding shares.
• Moshe Arkin is the sole shareholder and director of M. Arkin Dermatology Ltd., making him the indirect beneficial owner of the shares held by Arkin Dermatology.
• The aggregate beneficial ownership of Moshe Arkin, including direct and indirect holdings, totals 1,950,112 Ordinary Shares, which represents 65.31% of the Company's outstanding Ordinary Shares.
• The percentages are based on 2,785,787 Ordinary Shares outstanding as of June 11, 2025, as provided by the Issuer.
• Moshe Arkin made several open market purchases of Ordinary Shares between May 7, 2025, and May 29, 2025, acquiring a total of 105,122 shares.
• These purchases were made at prices ranging from $7.30 to $7.51 per share.

Sentiment

Score: 8

Explanation: The significant increase in beneficial ownership by a major insider, Moshe Arkin, through open market purchases, indicates strong confidence in the company's value and future, which is a highly positive signal for investors.

Positives

• Significant increase in insider ownership by a key director and major shareholder, Moshe Arkin, signaling strong confidence in the company's future prospects.
• The aggregate beneficial ownership of 65.31% by Moshe Arkin and his affiliated entity demonstrates a deep commitment to the company's long-term success.

Risks

• Increased concentration of ownership by a single individual and affiliated entity (65.31%) could potentially reduce the influence of minority shareholders in corporate decisions.

Future Outlook

The document does not contain any explicit forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

This Schedule 13D filing primarily concerns changes in beneficial ownership and does not provide broader industry context or trends.

Related Party Transactions

• Moshe Arkin, as a director and sole shareholder of M. Arkin Dermatology Ltd., engaged in open market purchases of Sol-Gel Technologies Ltd. Ordinary Shares. These transactions are considered related party dealings due to his significant influence and position within the company and its major shareholder.

Stakeholder Impact

• Shareholders: The increased stake by a major insider may instill greater confidence among existing shareholders and potential investors, suggesting strong belief in the company's value. However, the increased concentration of ownership could also reduce the influence of minority shareholders.

Key Dates

Recommendation

Keywords

Sol-Gel Technologies, SGLT, Schedule 13D, beneficial ownership, insider buying, Moshe Arkin, M. Arkin Dermatology, Ordinary Shares, SEC filing, shareholder stake